Top Markets
#1 Helium Helium +54.86%
#2 GEKKO GEKKO +53.94%
#3 ADO Protocol ADO Protocol +38.95%
#4 Pons Pons +36.17%
#5 TENDIES TENDIES +35.28%
#6 StonkBroker StonkBroker +32.23%
#7 Prom Prom +30.65%
#8 Collector Crypt Collector Crypt +29.96%
#9 o1.exchange o1.exchange +22.87%
#10 Cysic Cysic +20.09%
Coin of the day
Helium Helium
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
CARsgen Therapeutics Holdings Limited CARsgen Therapeutics Holdings Limited

CARsgen Therapeutics Holdings Limited

2171
Clasificación en acciones #9600
CARsgen Therapeutics Holdings Limited, a biopharmaceutical firm founded in... CARsgen Therapeutics Holdings Limited, a biopharmaceutical firm founded in Shanghai, China, in 2014, focuses on the discovery, development, and commercialization of advanced chimeric antigen receptor T (CAR-T) cell therapies. The company's efforts are directed toward treating various hematological malignancies and solid tumors across China and the United States. Its robust pipeline includes several key candidates: CT053, an autologous CAR-T product, is currently in a pivotal Phase II trial in China for relapsed/refractory multiple myeloma. Additionally, CT041, another autologous CAR-T, is undergoing Phase Ib/II clinical trials for advanced gastric/gastroesophageal junction and pancreatic cancers in China, and Phase Ib trials for comparable indications in the U.S. CARsgen is also advancing CT011, an autologous CAR-T candidate, through Phase I for patients with Glypican-3 positive advanced hepatocellular carcinoma, and CT032, an autologous CAR-T, in Phase I/II for B cell Non-Hodgkin's lymphoma in China. Furthermore, its pipeline features AB011, a humanized monoclonal antibody in Phase I for CLDN18.2 positive solid tumors in China, as well as CT017, an autologous Glypican-3-targeted CAR-T for hepatocellular carcinoma, and other promising therapies for solid tumors.
Precio por acción
$1.72
Última sincronización: 2026-08-28
Capitalización bursátil
$981.92M
Cambio (1 día)
-1.68%
Cambio (1 año)
-41.83%
País
CN
Comercio CARsgen Therapeutics Holdings Limited (2171)

Categoría

Healthcare
Historial del precio de la acción de CARsgen Therapeutics Holdings Limited (2171)
Precio más alto de cierre: $1.84 el 2026-08-01

Precio más bajo de cierre: $3.97 el 2021-06-01
Historial del precio de la acción de CARsgen Therapeutics Holdings Limited desde 2021 hasta 2026
Desempeño anual del precio de la acción
Año Rendimiento
2026 (TTM) 6.63%
2025 89.86%
2024 11.34%
2023 -48.93%
2022 -58.99%
2021 0.00%
Precio de la acción de empresas similares o competidoras
Empresa Precio de la acción Cambio 1a% País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $542.09 38.63%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.03K 44.13%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $121.53 -12.70%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $138.18 473.58%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $759.27 7.20%
CH